Search Results
Feb 13, 2026, 09:34 ET KOMISJA EUROPEJSKA ZATWIERDZA LEK UPLIZNA® FIRMY AMGEN W LECZENIU UOGÓLNIONEJ MIASTENII
kwalifikacji na etapie badania przesiewowego i randomizacji obejmowały klasyfikację choroby według Myasthenia Gravis Foundation of America (MGFA) stopnia II, III lub IV, wynik w skali MG-ADL w przedziale od 6 do 10, przy czym ponad 50% tego wyniku musiało wynikać z objawów innych niż oczne; wynik MG-ADL wynoszący
More news about: Amgen
Feb 13, 2026, 09:13 ET Notice of Pendency and Proposed Settlement of Stockholder Class Action Involving All Record and Beneficial Holders of CM Life Sciences III, Inc. Class A Common Stock on December 14, 2021
ACTION, SETTLEMENTHEARING, AND RIGHT TO APPEARTO: ALL RECORD AND BENEFICIAL HOLDERS OF CM LIFE SCIENCES III, INC. ("CMLS III") CLASS A COMMON STOCK WHO HELD SUCH STOCK IMMEDIATELY FOLLOWING THE REDEMPTION DEADLINE OF 5:00 PM ET ON DECEMBER 14, 2021, INCLUDING THEIR
More news about: JND Legal Administration
Feb 13, 2026, 09:10 ET CoreWeave, Inc. Securities Class Action Lawsuit Filed; Lead Plaintiff Deadline March 13, 2026
that CoreWeave's reliance on a single third-party data center supplier presented for CoreWeave's ability to meet customer demand for its services; and (iii) the foregoing was reasonably likely to have a material negative impact on CoreWeave's revenue.The CoreWeave class action lawsuit alleges
More news about: Robbins Geller Rudman & Dowd LLP
Feb 13, 2026, 09:10 ET KD INVESTOR ALERT: Kyndryl Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead the Class Action Lawsuit
were materially misstated; (ii) Kyndryl lacked adequate internal controls and at times materially understated issues with its internal controls; and (iii) as a result, Kyndryl would be unable to timely file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2025.The Kyndryl
More news about: Robbins Geller Rudman & Dowd LLP
Feb 13, 2026, 08:00 ET Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
a commercial-stage oncology company with an FDA-approved IL-2 receptor-directed immunotherapy for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL) following at least one prior systemic therapy;Established nationwide specialty distribution infrastructure,
More news about: Citius Oncology, Inc.
Feb 13, 2026, 08:00 ET Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Oncology successfully launched LYMPHIR™ (denileukin diftitox-cxdl) in the U.S. in December 2025 for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL) following at least one prior systemic therapy;Early physician adoption underway: Initial specialty distributor
More news about: Citius Pharmaceuticals, Inc.
Feb 13, 2026, 07:53 ET Jasmine Hartin Innocent of Possession and Common Assault Charges
Commissioner of Police Chester Williams later admitted on camera that there were no grounds for these accusations. Criminal procedure rules 2016, Section 2.1 (iii) of Belize subject to rule 2.8 "Every matter to be tried before a Magistrates Court shall be concluded within a period not exceeding 39 weeks (9 months)
More news about: AVI Media
Feb 13, 2026, 07:15 ET Alithya reports third quarter Fiscal 2026 results
earnings to support our operations; (ii) our ability to take advantage of business opportunities and meet our goals set in our three-year strategic plan; (iii) our ability to maintain and develop our business, including by broadening the scope of our service offerings, by leveraging artificial intelligence
More news about: Alithya Group inc.
Feb 13, 2026, 07:00 ET THE WENDY'S COMPANY REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS AND PROVIDES 2026 OUTLOOK
free cash flow as cash flows from operations minus (i) capital expenditures, (ii) expenditures related to the Company's franchise development fund and (iii) the net change in the restricted operating assets and liabilities of the advertising funds and any excess/deficit of advertising funds revenue over
More news about: The Wendy’s Company
Feb 13, 2026, 07:00 ET Enbridge Reports Record 2025 Financial Results, Reaffirms 2026 Financial Guidance, and Grows Secured Backlog to $39 Billion
demand for incremental egress, increasing deliveries of Canadian heavy oil to key refining markets in the U.S. Midwest (PADD II) and Gulf Coast (PADD III). MLO1 is expected to add 150 kbpd of Mainline system capacity, and 100 kbpd of FSP capacity via increased horsepower, upstream optimizations and terminal
More news about: Enbridge Inc.
Feb 13, 2026, 03:09 ET Notice convening the Annual General Meeting of AB Electrolux
cent for performance target (ii) and 20 per cent for performance target (iii). For the participants in Group 1 and 2 (Group Management), the granted Performance Shares based on the outcome of performance targets (i), (ii) and (iii) will be multiplied by 0.75–1.25 depending on the outcome of a relative
More news about: Electrolux Group
Feb 13, 2026, 03:06 ET Notice convening the Annual General Meeting of AB Electrolux
cent for performance target (ii) and 20 per cent for performance target (iii). For the participants in Group 1 and 2 (Group Management), the granted Performance Shares based on the outcome of performance targets (i), (ii) and (iii) will be multiplied by 0.75–1.25 depending on the outcome of a relative
More news about: Electrolux Group
Feb 12, 2026, 18:51 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pinterest, Inc. - PINS
reallocating resources to AI-focused roles and teams that drive AI adoption and execution, (ii) prioritizing AI–powered products and capabilities, and (iii) accelerating the transformation of its sales and go-to-market approach." On this news, Pinterest's stock price fell $2.49 per share, or 9.61%,
More news about: Pomerantz LLP
Feb 12, 2026, 18:42 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE
$10.41 per share, or 25.11%, to close at $31.04 per share on July 10, 2025. Then, on December 29, 2025, Ultragenyx announced that both its Phase III Orbit and Cosmic Studies had failed to "achieve statistical significance against the primary endpoints of reduction in annualized clinical fracture rate
More news about: Pomerantz LLP
Feb 12, 2026, 17:31 ET BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight
upregulated in blood cancers. By targeting this pathway, lisaftoclax demonstrates strong potential to undermine cancer cell survival. It has advanced to Phase III clinical trials for myelodysplastic syndrome and is being evaluated in multiple Phase I and II studies for additional hematologic malignancies, underscoring
More news about: DelveInsight Business Research, LLP
Feb 12, 2026, 17:30 ET Prologis Board of Directors Approves 6 Percent Increase in Quarterly Common Stock Dividend
local economic and political climates and conditions; (ii) changes in global financial markets, interest rates and foreign currency exchange rates; (iii) increased or unanticipated competition for our properties; (iv) risks associated with acquisitions, dispositions and development of properties, including
More news about: Prologis, Inc.
Feb 12, 2026, 17:19 ET W. P. Carey Inc. Announces Pricing of €1.0 Billion of Senior Unsecured Notes
(Financial Promotion) Order 2005, as amended (the "Financial Promotion Order")), (ii) fall within Article 49(2)(a) to (d) of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are other persons to whom it may otherwise lawfully be communicated or distributed under the Financial Promotion
More news about: W. P. Carey Inc.
Feb 12, 2026, 17:00 ET BLADEX ANNOUNCES NET PROFITS OF $56.0 MILLION OR $1.50 PER SHARE IN 4Q25 AND $226.9 MILLION OR $6.11 PER SHARE IN 2025
corresponding period.Tier 1 Capital ratio is calculated according to Basel III capital adequacy guidelines, and as a percentage of risk-weighted assets. Risk-weighted assets are estimated based on Basel III capital adequacy guidelines, utilizing internal-ratings based approach or "IRB" for credit
More news about: Bladex
Feb 12, 2026, 17:00 ET AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE
gold production starting in 2033. These projects include (i) a second shaft at Odyssey, (ii) the development of a satellite open pit at Marban and (iii) the development of the Wasamac underground project. Marban and Wasamac are located approximately 12 kilometres and 100 kilometres from the Canadian
More news about: Agnico Eagle Mines Limited
Feb 12, 2026, 16:45 ET Keurig Dr Pepper Announces New Directors and Governance Changes
timeframe or at all; (ii) risks relating to the ability to realize the anticipated benefits of the proposed JDE Peet's acquisition and subsequent spin-off; (iii) risks relating to significant costs related to the proposed JDE Peet's transactions; (iv) the expected financial and operating performance and future
More news about: Keurig Dr Pepper
Feb 12, 2026, 16:13 ET JOHN HANCOCK CLOSED-END FUNDS RELEASE EARNINGS DATA
HPSPreferred Income Fund III7/31
More news about: John Hancock Investment Management
Feb 12, 2026, 16:05 ET Legacy Education Delivers Strong Second Quarter Fiscal 2026 Results with 40% Revenue Growth and Impressive Enrollment Gains
the primary operations of our business, (ii) affording a view of our operating results that may be more easily compared to our peer companies, and (iii) enabling investors to consider our operating results on both a GAAP and adjusted non-GAAP basis (including following the integration period of our prior
More news about: Legacy Education Inc.
Feb 12, 2026, 16:02 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Sale of Endeavor Group Holdings, Inc. Class A Common Stock of Class Action Lawsuit and Upcoming Deadlines - EDR
consideration without any collar or contingent value right and offering only a de minimis dividend to shareholders that they shared with themselves; and (iii) disseminating a misleading Information Statement on January 15, 2025 that spoke in present tense about "fairness" and "best interests" to unaffiliated
More news about: Pomerantz LLP
Feb 12, 2026, 16:02 ET Pomerantz Law Firm Announces the Filing of a Class Action Against SLM Corporation and Certain Officers - SLM
effectiveness of SLM's loss mitigation and/or loan modification programs, as well as the overall stability of the Company's PEL delinquency rates; and (iii) as a result, Defendants' public statements made a materially false and misleading impression regarding SLM's business, operations, and prospects at
More news about: Pomerantz LLP
Feb 12, 2026, 16:02 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory
More news about: Pomerantz LLP